Skip to main content

Table 1 Baseline characteristics of 55 study patients

From: Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy

Variables

% (n) or mean ± SD

Age (yrs)

72 ± 11

Female gender

56.4% (31)

Diabetes mellitus

65.5% (36)

Hypertension

80.0% (44)

Current smoking

34.6% (19)

Dyslipidemia

41.8% (23)

Old stroke

27.3% (15)

Chronic kidney disease (stage I-IV)

27.3% (15)

End-stage renal disease on regular hemodialysis

27.3% (15)

Statin therapy*

50.9% (28)

ACEI/ARB therapy*

58.2% (32)

History of one leg amputation

18.2% (10)

Wound ulceration†

 

Grade 0

18.2% (10)

Grade 1

3.6% (2)

Grade 2

5.5% (3)

Grade 3

14.6 (8)

Group 4

60.0% (32)

  1. Data are expressed as mean ± SD or% (n).
  2. *Indicate the drug had already given to the patients ≥ 1 month.
  3. ACEI/ARB = angiotensin converting enzyme inhibitor/angiotensin II receptor type I blocker.